Powered by

European Business Development Conference 2018

Datum
-
Ort
Hannover
Adresse
Hannover Congress Centrum (hcc)
Theodor-Heuss-Platz 1-3
30175 Hannover
Anfahrt
Anfahrtsskizze
Art
Konferenz
Veranstalter
Biotechnologie-Industrie-Organisation Deutschland e.V. (BIO Deutschland e. V.)
Kontakt
Kirsten Lang
Projektassistentin
E-Mail: lang(at)biodeutschland.org

Matthias Bach
Marketingmanager
E-Mail: bach(at)biodeutschland.org
Links
EBDC 2018

Glossar

  • Ein Gen ist ein Teil der Erbinformation, der für die Ausprägung eines Merkmals verantwortlich ist. Es handelt sich hierbei um einen Abschnitt auf der DNA, der die genetische Information zur Synthese eines Proteins oder einer funktionellen RNA (z. B. tRNA) enthält.
  • Die somatischen Gentherapie dient der Kompensation von Gendefekten. Dabei wird die korrekte Form des defekten Gen in Körperzellen eingeschleust.
  • T-Lymphozyten oder kurz T-Zellen sind wichtige Zellen der Immunabwehr (weiße Blutkörperchen), die Fremdstoffe (Antigene) erkennen, wenn sie an die Oberfläche anderer Zellen gebunden sind. T-Lymphozyten sind zusammen mit B-Lymphozyten an der erworbenen (adaptiven) Immunantwort beteiligt, d.h. sie reagieren spezifisch auf einen Erreger.

Folgende Informationen sind nur auf Englisch verfügbar:

The European Business Development Conference (EBDC) is an annual event for leading decision makers from biotechnology and pharmaceutical firms.

About half of innovative drugs result from national – and especially international – collaborations. The EBDC provides a forum for making contacts and discussing topics and trends of relevance to the market.

Program Outline

Reboot for gene and cell therapy: challenges and perspectives
After setbacks in the 90s, gene therapy has returned to the R&D laboratories of pharma and biotech companies. Transfer of genes is not only key for the production of CAR- or TCR-T-cells to fight cancer. In 2017 the FDA approved the first gene therapy for a genetic disease, a form of retinal dystrophy. Treatments for diseases of the blood are also far along in the clinical pipeline. What are challenges and perspectives for cures based on gene therapy?

Exits for Biotechs: Before and After the IPO
Besides the advantages of a public offering around the access to growth capital at the time of an IPO and thereafter, the preparation of the operation can often be demanding for private organization. Also, the time after a company went public has its challenges. CEOs and CFOs of European biotech companies who chose the pan-European exchange Euronext for their IPO discuss their experiences with other experts and share best practice examples in this session.

Big Data and Digitization: Perspectives for drug development and patient care
The availability of large amounts of biomarker and medical data is revolutionizing medicine and drug development. How can these vast amounts of data best be used to improve R&D and clinical trials? How will big data impact the time from drug discovery to market launch and will the use of digital data revolutionize patient care?

Spotlight talks: Unmet medical needs

Besides the sessions the program will offer dedicated slots for one-to-one partnerings, company presentations of innovative biotechs and a networking dinner.

Seiten-Adresse: https://www.gesundheitsindustrie-bw.de/de/veranstaltung/european-business-development-conference-2018/